No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
FunPep: Extraordinary Report
FanPapp --- Business Plan and Growth Potential
FanPep <4881> announced on the 31st details regarding its business plan and growth potential. The company aims to secure income from the development stage as a Business model for drug discovery ventures and to earn revenue based on product sales after market launch. The company acts as a bridge connecting the research achievements of Universities to pharmaceutical companies. The main risk information for drug discovery ventures includes "the uncertainty of pharmaceutical research and development" and "dependence on specific partnership agreements," among others. As a response strategy, the company plans to implement measures.
FanPep has signed a joint research agreement with BIOASTER regarding antibody-inducing peptides.
Fanpeps <4881> announced on the 31st that it has entered into a joint research agreement with the French public research institution BIOASTER to optimize in vitro assay methods for antibody production of its antibody-inducing peptides (therapeutic Vaccine). In this research, the assessment method development for the company's Vaccine candidates will be carried out utilizing BIOASTER's expertise in assay method development and technology transfer. The company's antigen design technology and BIOASTER's cutting-edge technology and expertise in immunology will be leveraged.
April 1st [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Star Mica Holdings <2975> 920 yen (3/31) engages in the revival and distribution business of used condominiums. The first-quarter financial results have been announced. The operating profit is 2.306 billion yen (an increase of 86.4% compared to the previous year). The renovation condominium business has actively purchased properties, resulting in an increase in Shareholding units. Additionally, in terms of sales, the diversification of exit strategies for owner change properties has been effective. The operating profit for the fiscal year ending November 2025 is projected to be 6.298 billion yen (an increase of 14.0% compared to the previous term).
Strong performance, with an upward trend in the Dow Inc average leading to dominance in buying on dips.
[Emerging Markets Individual Stocks Global Strategy] Today's Emerging Markets are expected to show a stable development. On March 31, the US Stocks market saw the Dow Inc rise by 417.86 points (+1.00%) to 42,001.76, rebounding for the first time in four days. Caution over Trump's tariffs and the diminishing expectations of a ceasefire between Russia and Ukraine weighed on stock prices. On the other hand, the unexpected rise in the Chicago Purchasing Managers' Index and the month-end and quarter-end 'dressing buys' supported the market. Today's Emerging Markets are favorable for Buy.
FanPep, Kids Bio, and others.
The forecast for this period's operating profit has been revised down to 0.39 billion yen from 1.619 billion yen.
